StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience total assets

Total assets on the balance sheet at the end of each period.

Niagen Bioscience's total assets was $108.69M at Sep 30, 2026. For fiscal 2025 it was $106.41M, up 55.8% from the year before. Over ten years it grew 19.0% a year on average. The highest annual figure on record is $106.41M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$106.41M+55.8%
FY2024Dec 31, 2024$68.28M+24.2%
FY2023Dec 31, 2023$54.96M+1.7%
FY2022Dec 31, 2022$54.06M-6.5%
FY2021Dec 31, 2021$57.84M+50.8%
FY2020Dec 31, 2020$38.36M-4.7%
FY2019Dec 31, 2019$40.25M-4.7%
FY2018Dec 31, 2018$42.23M-32.7%
FY2017Dec 30, 2017$62.72M+217.6%
FY2016Dec 31, 2016$19.75M+5.3%
FY2015Jan 2, 2016$18.75M+62.8%
FY2014Jan 3, 2015$11.52M+28.2%
FY2013Dec 28, 2013$8.99M-0.5%
FY2012Dec 29, 2012$9.03M+44.1%
FY2011Dec 31, 2011$6.27M-3.6%
FY2010Jan 1, 2011$6.51M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$108.69M+10.8%
Q2 FY2026Jun 30, 2026$106.59M+16.5%
Q1 FY2026Mar 31, 2026$114.33M+40.6%
Q4 FY2025Dec 31, 2025$106.41M+55.8%
Q3 FY2025Sep 30, 2025$98.14M+73.6%
Q2 FY2025Jun 30, 2025$91.53M+69.4%
Q1 FY2025Mar 31, 2025$81.34M+50.4%
Q4 FY2024Dec 31, 2024$68.28M+24.2%
Q3 FY2024Sep 30, 2024$56.52M+5.7%
Q2 FY2024Jun 30, 2024$54.04M+1.6%
Q1 FY2024Mar 31, 2024$54.08M+0.6%
Q4 FY2023Dec 31, 2023$54.96M+1.7%
Q3 FY2023Sep 30, 2023$53.48M+17.1%
Q2 FY2023Jun 30, 2023$53.17M+14.1%
Q1 FY2023Mar 31, 2023$53.77M+1.6%
Q4 FY2022Dec 31, 2022$54.06M-6.5%
Q3 FY2022Sep 30, 2022$45.67M-24.5%
Q2 FY2022Jun 30, 2022$46.61M-29.2%
Q1 FY2022Mar 31, 2022$52.93M-23.3%
Q4 FY2021Dec 31, 2021$57.84M+50.8%
Q3 FY2021Sep 30, 2021$60.45M+61.6%
Q2 FY2021Jun 30, 2021$65.84M+56.8%
Q1 FY2021Mar 31, 2021$68.99M+93.7%
Q4 FY2020Dec 31, 2020$38.36M-4.7%
Q3 FY2020Sep 30, 2020$37.42M-13.3%
Q2 FY2020Jun 30, 2020$41.99M-5.7%
Q1 FY2020Mar 31, 2020$35.61M-15.1%
Q4 FY2019Dec 31, 2019$40.25M-4.7%
Q3 FY2019Sep 30, 2019$43.14M-8.3%
Q2 FY2019Jun 30, 2019$44.54M-14.6%
Q1 FY2019Mar 31, 2019$41.93M-27.0%
Q4 FY2018Dec 31, 2018$42.23M-32.7%
Q3 FY2018Sep 30, 2018$47.02M+12.5%
Q2 FY2018Jun 30, 2018$52.17M+58.5%
Q1 FY2018Mar 31, 2018$57.45M+190.8%
Q4 FY2017Dec 30, 2017$62.72M+234.3%
Q3 FY2017Sep 30, 2017$41.80M–
Q2 FY2017Jul 1, 2017$32.92M–
Q4 FY2016Dec 31, 2016$19.75M–
Q3 FY2016Oct 1, 2016$18.76M–

More Niagen Bioscience figures

See a number that looks wrong?